Company profile
Quaisr | SimOps for engineering
Simulation for the machine-learning era.
Financial period: 1 Jul 2023 to 30 Jun 2024
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last confirmation statement made up date
Last accounts made up date
CS01 | Transaction MzQzOTgxODk0MWFkaXF6a2N4
Published 16 Oct 2024 11:17
CH01 | Transaction MzQzOTYwNDc4MGFkaXF6a2N4
Published 15 Oct 2024 02:59
PSC04 | Transaction MzQzOTYwNDc3NWFkaXF6a2N4
Published 15 Oct 2024 02:59
SH01 | Transaction MzQzOTYwNDc3NmFkaXF6a2N4
Published 15 Oct 2024 02:59
Company registered at Companies House
1 Jan 2024 to 31 Dec 2026
OMICSENS aims to develop a radically new omics measurement platform that would be initially applied to improve non-small cell lung cancer (NSCLC) prognosis by ensuring a timely and accurate detection of Tyrosine Kinase Inhibitor (TKI) resistance associated to Epidermal Growth Factor Receptor (EGFR) mutations. Subsequently, OMICSENS will be used to improve...
